Growing M&As
New Page 3
CRAMS Deals
Deals involving sharing of intellectual property and licensing
of technologies are increasing in number with not only large global companies,
but even mid-sized companies resorting to outsourcing. However, these deals are
smaller in size.
Key deals during November 2007 to January 2008 period, include the contract
research deals between Nicholas Piramal and Merck, and Jubilant Biosys and
Forest Laboratories.
|
Primary Company
|
Deal Partner
|
Deal Date
|
Deal Details
|
|
Ajanta Pharma
|
Arrow Pharma (Canada)
|
Nov-07
|
Agreement to market Nimesulide in Brazil
|
|
Nicholas Piramal
|
Merck (New Jersey, US)
|
Nov-07
|
R&D deal for new drugs for two selected categories.
Nicholas Piramal will be responsible for developing, pre-clinical trials,
clinical trials phase I and II. It will receive milestone payment of $175
million per target and also royalty payment on sale. of any of these
developed products.
|
|
Strides Arcolab
|
Aspen Pharmacare (Durban, South Africa)
|
Nov-07
|
Both the companies have entered into four transactions:
A 50% joint venture to develop, manufacture and
commercialize on a global basis a range of oncology products.
Strides' acquisition of a 51% interest in Aspen's UK
based subsidiary Co-pharma Limited.
Strides' acquisition of 80% interest in Formula
Naturelle (Pty) Ltd which will, in turn own a group of nutraceutical
products currently marketed by Aspen
Aspen's acquisition of 50% interest in Strides Latin
American operations |
|
Dr. Reddy's Laboratories
|
Sygnis Pharma AG (Heidelberg, Germany)
|
Nov-07
|
Agreement to supply Active Pharmaceutical Ingredient AX200
to Sygnis for developing treatment of neurodegenerative disorders.The
agreement also includes marketing of AX200.
|
|
Jubilant Biosys
|
Forest Laboratories (New York, US)
|
Dec-07
|
Agreement to discover small molecule drug candidates for a
novel metabolic disorder target. Jubilant Biosys will be responsible for
drug discovery work and Forest Lab for pro-clinical development. Forest
Lab will own the drug discovered and will have worldwide commercialization
rights.
|
|
Strides Arcolab
|
Sagent Pharmaceuticals (Illinois, US)
|
Dec-07
|
Both the companies have entered into an agreement to
develop, market and supply injectable products in US.The agreement will
initially cover 25 products. As per the agreement, Strides will develop
and supply the injectable products, which Sagent will market in the US.
|
|
Biocon
|
IATRICa (based in Baltimore, Maryland, US)
|
Jan-08
|
The two companies have entered into a partnership to
co-develop immunoconjugates for targeted immunotherapy of cancers and
infectious diseases. Both the companies will co-develop products based on
IATRICa's technology and Biocon's expertise in clinical research, drug
discovery and biologics manufacturing.
|
|
Cadila Healthcare
|
Prolong Pharmaceuticals Inc., (New Jersey, US)
|
Jan-08
|
The two companies have entered into a collaboration to
develop PEG-EPO, a therapeutic protein for the treatment of anemia.
|
Page(s) 1 2 |
